2015
DOI: 10.1073/pnas.1510876112
|View full text |Cite
|
Sign up to set email alerts
|

Allosteric N-WASP activation by an inter-SH3 domain linker in Nck

Abstract: Actin filament networks assemble on cellular membranes in response to signals that locally activate neural Wiskott-Aldrich-syndrome protein (N-WASP) and the Arp2/3 complex. An inactive conformation of N-WASP is stabilized by intramolecular contacts between the GTPase binding domain (GBD) and the C helix of the verprolin-homology, connector-helix, acidic motif (VCA) segment. Multiple SH3 domaincontaining adapter proteins can bind and possibly activate N-WASP, but it remains unclear how such binding events relie… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
24
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
6
2
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 30 publications
(26 citation statements)
references
References 59 publications
2
24
0
Order By: Relevance
“…Arp2/3 was purchased from Cytoskeleton, Inc. Profilin, cofilin, and utrophin actin binding domain (1-261) were purified as previously described (Bieling et al, 2016). 35 Motility assay Similar to a previously described motility assay (Okrut, Prakash, Wu, Kelly, & Taunton, 2015), 2 µl of 0.5% 3 µm streptavidin polystyrene beads (Bangs Laboratories) are incubated with 1 µM biotin-p14 cytoplasmic tail peptide in 10 mM HEPES (pH 7.5), 1 mg/ml BSA and 50 mM KCl 40 for 10 min at room temperature. Peptide-coated beads are diluted eight-fold into motility buffer (10 mM HEPES, 2 mM MgCl2, 50 mM KCl, 50 mM NaCl, 1 mg/ml BSA, 2.5 mM ATP, 5 mM TCEP), containing 0.1 µM Grb2 (20% labeled), 0.2 µM N-WASP, 9 µM actin, 0.075 µM arp2/3, 0.05 µM capping protein, 2.6 µM profilin, 3.5 µM cofilin and incubated for 15 min at room temperature while rotating.…”
Section: Drug Treatmentmentioning
confidence: 99%
“…Arp2/3 was purchased from Cytoskeleton, Inc. Profilin, cofilin, and utrophin actin binding domain (1-261) were purified as previously described (Bieling et al, 2016). 35 Motility assay Similar to a previously described motility assay (Okrut, Prakash, Wu, Kelly, & Taunton, 2015), 2 µl of 0.5% 3 µm streptavidin polystyrene beads (Bangs Laboratories) are incubated with 1 µM biotin-p14 cytoplasmic tail peptide in 10 mM HEPES (pH 7.5), 1 mg/ml BSA and 50 mM KCl 40 for 10 min at room temperature. Peptide-coated beads are diluted eight-fold into motility buffer (10 mM HEPES, 2 mM MgCl2, 50 mM KCl, 50 mM NaCl, 1 mg/ml BSA, 2.5 mM ATP, 5 mM TCEP), containing 0.1 µM Grb2 (20% labeled), 0.2 µM N-WASP, 9 µM actin, 0.075 µM arp2/3, 0.05 µM capping protein, 2.6 µM profilin, 3.5 µM cofilin and incubated for 15 min at room temperature while rotating.…”
Section: Drug Treatmentmentioning
confidence: 99%
“…8). First, N-WASp relies on an Nck SH3 interdomain linker region for its ability to recruit and activate Arp2/3 (Okrut et al, 2015), and this linker also contributes to phase separation (Banjade et al, 2015). Next, the high-affinity binding of N-WASp to Nck disrupts the SH3-mediated autoinhibition of Nck (Takeuchi et al, 2010), which may in turn allow subsequent binding of low-affinity interactors, such as dynamin.…”
Section: Discussionmentioning
confidence: 99%
“…the Wave Regulatory Complex). Upstream signaling molecules stimulate the activity of these NPFs by disruption auto-inhibition, either allosterically (Rohatgi et al, 2000;Padrick et al, 2008) or competitively (Okrut et al, 2015). The ability of LC3 to promote actin nucleation by JMY, however, does not involve disrupting an autoinhibitory interaction, but rather the enhancement of a previously unsuspected nucleation activity associated with JMY's N-terminal LIR sequence.…”
Section: Discussionmentioning
confidence: 99%